Theramir Ltd, a pioneering Limassol-based biotech startup specializing in cutting-edge oncology solutions, is thrilled to announce the signing of the groundbreaking MiRACULOUS research program. This initiative, backed by the Research and Innovation Foundation under the RESTART 2016-2020 initiative, is funded by the European Union's NextGenerationEU and the Republic of Cyprus, with a generous grant of €200,000 over two years.

MiRACULOUS – standing for "MicroRNA-based Innovative Formulations for the Regulation And Control of Oncological Unhealing Sores" – addresses the urgent need for effective treatments for malignant wounds in oncology patients, which pose a substantial medical and economic challenge globally. The program aims to harness the potential of extracellular vesicles derived from mesenchymal stem cells, in synergy with the regenerative properties of atelocollagen-based hydrogels combined with natural extracts, to deliver therapeutic microRNAs directly to wound sites. This aligns with the Cyprus S3Cy's Smart Specialization Areas, furthering public health and enhancing quality of life.

Dr. Marianna Prokopi-Demetriades coordinates this venture, in partnership with Promed Bioscience, RSL Revolutionary Labs, and VetEx Machina. "MiRACULOUS epitomizes the fusion of innovation and empathy," stated Dr. Prokopi-Demetriades. "We are committed to transforming advanced research into real-world health benefits, advancing the frontiers of oncology care and patient healing." The expertise of the consortium spans biotechnology, skin health, oncology, and regenerative medicine, marking a crucial leap toward innovative healthcare solutions. The official signing ceremony symbolizes the start of this promising collaboration, uniting these dynamic forces in the field of biotech.

For further details about the MiRACULOUS program and Theramir Ltd's role in revolutionizing oncology care, contact [email protected].

About Theramir Ltd: Theramir Ltd is dedicated to developing groundbreaking healthcare solutions. With a deep commitment to research and innovation, we strive to bring new hope to patients around the world.